Join Growin Stock Community!

浩鼎4174.TW Overview

TW StockBiotech. & Medical
(No presentation for 4174)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

浩鼎（4174）Overall Performance

浩鼎（4174）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

浩鼎（4174） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

浩鼎（4174）Key Information

浩鼎（4174）Profile

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.

浩鼎（4174）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-167.96%
Net Margin
-4790.78%
Revenue Growth (YoY)
-29.13%
Profit Growth (YoY)
-19.32%
3-Year Revenue Growth
113.91%
3-Year Profit Growth
-42.03%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-167.96%
Net Margin
-4790.78%
Revenue Growth (YoY)
-29.13%
Profit Growth (YoY)
-19.32%
3-Year Revenue Growth
113.91%
3-Year Profit Growth
-42.03%
default symbol

4174

浩鼎

39.85D

-1.76%

(-0.02)

  • When is 4174's latest earnings report released?

    The most recent financial report for 浩鼎 (4174) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4174's short-term business performance and financial health. For the latest updates on 4174's earnings releases, visit this page regularly.

  • What is the operating profit of 4174?

    According to the latest financial report, 浩鼎 (4174) reported an Operating Profit of -496.61M with an Operating Margin of -4,719.73% this period, representing a growth of 7.01% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4174's revenue growth?

    In the latest financial report, 浩鼎 (4174) announced revenue of 10.52M, with a Year-Over-Year growth rate of -54.21%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4174 have?

    At the end of the period, 浩鼎 (4174) held Total Cash and Cash Equivalents of 907.54M, accounting for 0.24 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4174 go with three margins increasing?

    In the latest report, 浩鼎 (4174) did not achieve the “three margins increasing” benchmark, with a gross margin of -211.59%%, operating margin of -4,719.73%%, and net margin of -4,934.61%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4174's profit trajectory and future growth potential.

  • Is 4174's EPS continuing to grow?

    According to the past four quarterly reports, 浩鼎 (4174)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.78. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4174?

    浩鼎 (4174)'s Free Cash Flow (FCF) for the period is -59.79M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 20.34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.